Clinical trials: Nash
Diabetes Mellitus, Type 2, Metabolic Associated Fatty Liver Disease
Correlation Between Serum Nociceptin and Sympathetic Nerve Activity in Diabetic Patients With MAFLD
This observational study aims to investigate the relationship between serum nociceptin levels and sympathetic nervous system activity in patients with both type 2 diabetes mellitus (T2DM) and metabolic associated fatty liver…
- Trial name
- NCT07663682
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Second Hospital of Shanxi Medical University
Non Alcoholic Steatohepatitis
The Effects of Synbiotics Supplement on Biochemical Factors and Hepatic Fibrosis in Patients With Nonalcoholic Steatohepatitis
To study the effects of synbiotics supplement on lipid profile, liver enzymes, inflammatory factors and hepatic fibrosis in patients with Nonalcoholic Steatohepatitis (NASH), 50 patients who referred to Gastrointestinal (GI)…
- Trial name
- NCT01791959
- Testing
- synbiotic
- Volunteers
- 54 people
- Sponsor
- National Nutrition and Food Technology Institute
Nonalcoholic Fatty Liver Disease
Role of Pioglitazone and Berberine in Treatment of Non-Alcoholic Fatty Liver Disease
The purpose of this study is to evaluate the effects and safety of pioglitazone and berberine on the basis of lifestyle intervention to non-alcoholic fatty liver disease patients with impaired glucose regulation or type 2…
- Trial name
- NCT00633282
- Testing
- Life style intervention, pioglitazone, berberine
- Where
- 3 sites in China
- Volunteers
- 184 people
- Sponsor
- Xin Gao
Non-Alcoholic Steatohepatitis (NASH)
Phase 1 Study to Evaluate Safety of GR-MD-02 in Subjects With Non-Alcoholic Steatohepatitis (NASH) and Advanced Fibrosis
The primary objective of this study is to characterize the safety, tolerability and dose-limiting toxicities (DLTs) for GR-MD-02 when administered intravenously to subjects with biopsy-proven NASH with advanced liver fibrosis.
- Trial name
- NCT01899859
- Testing
- GR-MD-02
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Galectin Therapeutics Inc.
Liver Transplant; Complications, NAFLD
Safety, Tolerability, and Efficacy of Saroglitazar Mg 4 mg in Liver Transplant Recipients With Nonalcoholic Fatty Liver Disease (NAFLD)
This is a phase 2A, single center, open-label, single-arm, 24-week study to evaluate the safety, tolerability and efficacy of Saroglitazar Magnesium 4 mg in liver transplant recipients with NAFLD.
- Trial name
- NCT03639623
- Testing
- Saroglitazar
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Zydus Therapeutics Inc.
Obstructive Sleep Apnea, Metabolic Dysfunction-Associated Steatotic Liver Disease
Association Between Metabolic Associated Fatty Liver Disease and Obstructive Sleep Apnea
Association between Metabolic Associated Fatty Liver Disease and Obstructive Sleep Apnea
- Trial name
- OSA/MAFLD (NCT07716995)
- Volunteers
- 127 people
- Sponsor
- Assiut University
Non-alcoholic Fatty Liver Disease
Pradaxa Tablet Proton Pump Inhibitor (PPI) Bioavailability (BA) Study in Japan
The primary objective of this trial is to investigate the relative Bioavailability (BA) of tablet formulation of Dabigatran etexilate (DE) with and without co-administration of rabeprazole in healthy male subjects.
- Trial name
- NCT03143166
- Testing
- Dabigatran Etexilate, Rabeprazol sodium
- Where
- Japan
- Volunteers
- 36 people
- Sponsor
- Boehringer Ingelheim
Non-Alcoholic Fatty Liver Disease
Effects of Fecal Microbiota Transplantation on Weight in Obese Patients With Non-alcoholic Fatty Liver Disease
The worldwide impact of obesity suggests an urgent need for solutions to decrease its burden on modern society. It has been generally understood that obesity is caused by a simple imbalance in the intake of energy in the form of…
- Trial name
- NCT04594954
- Testing
- Diet, FMT, Physical Activity
- Where
- India
- Volunteers
- 110 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
NASH With Fibrosis, Weight Loss
Fibrosis Reduction in Non Alcoholic Steatohepatitis
Background: Non-Alcoholic Steatohepatitis (NASH) represents one of the stages of Non-Alcoholic Fatty Liver Disease (NAFLD) with a very high risk to evolve in cirrhosis and hepato-carcinoma.
- Conditions
- NASH With Fibrosis, Weight Loss, Bariatric Surgery Candidate
- Trial name
- FRIN (NCT05798702)
- Testing
- roux -en-y- gastric bypass, intensive life style modification
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Non-Alcoholic Fatty Liver Disease, Central Obesity
12-Month Once-a-week HIIT Improves Body Adiposity and Liver Fat
Obesity and non-alcoholic fatty liver disease (NAFLD) are two related growing epidemics that are becoming pressing public health concerns.
- Trial name
- NCT03912272
- Testing
- High-intensity Interval Training, Usual Care Control
- Where
- Hong Kong
- Volunteers
- 160 people
- Sponsor
- The University of Hong Kong
Hepatocellular Carcinoma (HCC), MASLD-HCC
Single-Cell Profiling of Liver-infiltrating Immune Cells of Patients with NASH- and Virus-related HCC: Implications for Immunotherapy
The goal of this observational study is to learn about the the immune landscape of HCC arising from different etiology, such as MASLD and viral hepatitis, at single cell level.
- Conditions
- Hepatocellular Carcinoma (HCC), MASLD-HCC, HCV_HCC
- Trial name
- 1003rcr2022_72 (NCT06899763)
- Where
- Italy
- Volunteers
- 6 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Non-Alcoholic Fatty Liver Disease, Type 2 Diabetes
Quantifying Hepatic Mitochondrial Fluxes in Humans
In this study the investigators will quantitate hepatic mitochondrial fluxes in T2D patients with NAFL and NASH before and after 16-weeks treatment with the insulin sensitizer pioglitazone
- Conditions
- Non-Alcoholic Fatty Liver Disease, Type 2 Diabetes, Mitochondrial Metabolism Disorders
- Trial name
- NCT05305287
- Testing
- Pioglitazone
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
NAFLD, Overweight and Obesity
The Role of Dietary Carbohydrate and Fat Availability in the Regulation of Hepatic Lipid Content
The purpose of this study is to investigate dietary compositions effect on liverfat measured by magnetic resonance imaging.
- Conditions
- NAFLD, Overweight and Obesity, Metabolic Syndrome, Diabetes
- Trial name
- LICARB (NCT04581421)
- Testing
- High Carb Low Fat Diet, Low Carb High Fat Diet
- Where
- Denmark
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Hvidovre University Hospital
Hepatic Ischemia-reperfusion Injury, Non-alcoholic Fatty Liver Disease
Mechanisms of Macrophage Polarization in HIRI in Patients With NAFLD
To better understand the occurrence of hepatic ischemia-reperfusion injury (IRI) in patients with non-alcoholic fatty liver disease (NAFLD) and the role of macrophage polarization in this process, this study will retrospectively…
- Trial name
- NCT06950710
- Testing
- NAFLD
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Zhifeng Gao
Metabolic Syndrome
Non-invasive Evaluation of Hepatic Fibrosis in Patients With the Metabolic Syndrome
Non-alcoholic fatty liver disease (NAFLD) is now recognised as the hepatic complication of the metabolic syndrome of insulin resistance.
- Trial name
- NCT00399932
- Where
- Belgium
- Volunteers
- 75 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
NAFLD, Insulin Resistance
Determination of Insulin-stimulated Hepatic Glucose Uptake by PET-CT Measurements
In the absence of excessive alcohol consumption, increased levels of fat in the liver (>5%) are diagnosed as non-alcoholic fatty liver (NAFL).
- Conditions
- NAFLD, Insulin Resistance, Overweight and Obesity
- Trial name
- ISGU (NCT04938544)
- Where
- Netherlands
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Maastricht University Medical Center
NASH - Nonalcoholic Steatohepatitis
Namodenoson in the Treatment of Non-Alcoholic Steatohepatitis (NASH)
Subjects with biopsy-proven NASH will be randomly assigned in a 2:1 ratio to oral doses of namodenoson 25 mg every 12 hours or matching placebo every 12 hours for 36 weeks.
- Trial name
- NCT04697810
- Testing
- Namodenoson
- Where
- 24 sites in Bosnia and Herzegovina, Bulgaria and 4 more
- Volunteers
- 114 people
- Sponsor
- Can-Fite BioPharma
NASH - Nonalcoholic Steatohepatitis
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3
- Trial name
- NATiV3 (NCT04849728)
- Testing
- IVA337
- Where
- 459 sites in United States, Argentina and 22 more
- Volunteers
- 1,000 people
- Sponsor
- Inventiva Pharma
Healthy Volunteers
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of TB-840 in Healthy Subjects
TB-840(Agonist of RORα) is a candidate for NASH treatment that activates RORα(Retinoid-related orphan receptor) and its target validation for RORα and potential as a NASH treatment.
- Trial name
- NCT05045534
- Where
- South Korea
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Therasid Bioscience
Insulin Resistance, Hyperinsulinemia
Effect of Alpelisib in Healthy Volunteers
The goal of this clinical trial is to test a single dose of the phosphoinositide-3-kinase (PI3K) inhibitor alpelisib versus placebo in healthy volunteers.
- Conditions
- Insulin Resistance, Hyperinsulinemia, Dyslipidemias
- Trial name
- NCT05733455
- Testing
- Alpelisib 150 mg [Piqray], 2 overencapsulated tablets (total: 300 mg), FreeStyle Libre Pro, Oral glucose tolerance test (OGTT) with Trutol glucose beverage
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Columbia University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.